AI English summary of an SEC filing — figures as filed
Pfizer PFEPfizer said Total revenues for Q2 2024 were $13.3 billion, up 2% from $13.0 billion a year earlier, and that revenues for the first six months fell 11% to $28.2 billion from $31.5 billion.
Key points
AI summaryPfizer said Total revenues for Q2 2024 were $13.3 billion, up 2% from $13.0 billion a year earlier, and that revenues for the first six months fell 11% to $28.2 billion from $31.5 billion.
Excluding Comirnaty and Paxlovid, Pfizer said Total revenues for Q2 rose $1.6 billion, or 14%, on an operational basis, citing revenues from legacy Seagen products acquired in December 2023 and growth from the Vyndaqel family and Eliquis.
Pfizer said its loss from continuing operations before taxes was $103 million for Q2 2024, compared with income of $2.3 billion a year earlier. It said it will receive $1.2 billion in merger consideration from AbbVie's acquisition of Cerevel and expects to recognize a gain of about $100 million in Q3.
Pfizer said the Phase 3 CIFFREO study of fordadistrogene movaparvovec did not meet its primary endpoint in June 2024, and that key 1 secondary endpoints also did not show a significant difference. It recorded a $240 million intangible asset impairment charge in Q2 and said it expects to record a charge of about $400 million in Q3 following a decision to sell one of its facilities.
Key figures
Quarter ended June 30, 2024
- Revenue
- $13.3B
- Net income
- $41M
- EPS
- $0.01
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q2 and First Six Months Total Revenue Changes
Pfizer said Total revenues for Q2 2024 were $13.3 billion, up 2% from $13.0 billion a year earlier, and that revenues for the first six months fell 11% to $28.2 billion from $31.5 billion.
Source · Based on the MD&A text of the filing
Revenue Excluding Comirnaty and Paxlovid and Growth Drivers
Excluding Comirnaty and Paxlovid, Pfizer said Total revenues for Q2 rose $1.6 billion, or 14%, on an operational basis, citing revenues from legacy Seagen products acquired in December 2023 and growth from the Vyndaqel family and Eliquis.
Source · Based on the MD&A text of the filing
Pre-Tax Results and Cerevel Proceeds
Pfizer said its loss from continuing operations before taxes was $103 million for Q2 2024, compared with income of $2.3 billion a year earlier. It said it will receive $1.2 billion in merger consideration from AbbVie's acquisition of Cerevel and expects to recognize a gain of about $100 million in Q3.
Source · Based on the MD&A text of the filing
CIFFREO Study Results and Related Charges
Pfizer said the Phase 3 CIFFREO study of fordadistrogene movaparvovec did not meet its primary endpoint in June 2024, and that key 1 secondary endpoints also did not show a significant difference. It recorded a $240 million intangible asset impairment charge in Q2 and said it expects to record a charge of about $400 million in Q3 following a decision to sell one of its facilities.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…